Maia Biotech Q2 FY26 net loss widens 49% to $7.94 million - MAIA News | RalliesMaia Biotech Q2 FY26 net loss widens 49% to $7.94 million
M
MAIA• Funding and clinical updates
- Net proceeds of about $33 million from March equity offerings are expected to fully fund the ongoing Phase 3 THIO-104 NSCLC trial.
- Phase 2 THIO-101 Part C showed a 90.5% disease control rate in 21 efficacy-evaluable 3L NSCLC patients as of July 6, 2026.
Quarterly results widen as expenses rise
- Maia Biotechnology posted a net loss of $7.94 million in Q2 2026, widening 49% from a year earlier.
- Operating loss widened 61% to $8.32 million as R&D expense climbed 81% to $5.64 million, and G&A rose 30% to $2.68 million.
- Interest income increased 197% to $236,320; other income turned positive to $373,664, supported by $207,173 in grant income.
